Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $401.8 million.

  • Tarsus Pharmaceuticals' Cash & Current Investments rose 2678.17% to $401.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.8 million, marking a year-over-year increase of 2678.17%. This contributed to the annual value of $291.4 million for FY2024, which is 2811.0% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Cash & Current Investments of $401.8 million as of Q3 2025, which was up 2678.17% from $381.1 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Cash & Current Investments registered a high of $407.9 million during Q1 2025, and its lowest value of $156.2 million during Q1 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' Cash & Current Investments averaged around $254.1 million, with its median value being $227.4 million (2023).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Cash & Current Investments skyrocketed by 23261.5% in 2021, and later plummeted by 2737.25% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Cash & Current Investments (Quarter) stood at $171.8 million in 2021, then increased by 26.31% to $217.0 million in 2022, then increased by 4.8% to $227.4 million in 2023, then increased by 28.11% to $291.4 million in 2024, then soared by 37.91% to $401.8 million in 2025.
  • Its last three reported values are $401.8 million in Q3 2025, $381.1 million for Q2 2025, and $407.9 million during Q1 2025.